Abstract
Linomide [N-methyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide] is a new immunomodulator from Phamacia Laboratories, Helsingborg, Sweden. Linomide (LS-2616) has delayed hypersensitivity in rat skin, potentiates mouse natural killer cell activity, and stimulates polyclonal T-cell activation. It has been shown that LS-2616 abolishes the effects of continuous cyclosporine treatment in experimental models. Crystal structure of LS-2616 has been undertaken as a first step in the establishment of a possible structure–function relationship for the drug. Crystals of LS-2616 (C18H16N2O3) obtained from methylene chloride are monoclinic, of space group P21/a with the following crystallographic parameters: a = 8.793(1) Å, b = 22.349(3) Å, c = 7.808(1) Å, β = 92.96(1)°, V = 1532.3(6) Å3, ρobs = 1.34 Mg/m3, ρcalc = 1.337 Mg/m3, and Z = 4. The structure was solved with CAD-4 data using MULTAN programs and refined to a final R value of 0.041. The N-methyl carboxamide is in the cis configuration and is turned away from the quinoline ring by 87°. FK506 is a novel 23-membered macrolide lactone which is currently used for bone marrow and organ transplantations. The crystal structure of FK506 has been published. The absolute configuration of FK506 was established as a cis-amide which contains a L-pipecolic acid moiety. Preliminary modeling studies of FK506 with LS-2616 revealed that this cis conformation for the N-methyl carboxamide leads to a lower binding energy than the corresponding trans conformation. The plane of the phenyl group is inclined by 95° to the carboxamide plane. The molecule has the familiar herring-bone type of packing, characteristic of the polyphenyl molecules, stabilized by O–H ⋅ ⋅ ⋅ O and C–H ⋅ ⋅ ⋅ O hydrogen bonds involving the hydroxyl group and the ketone substituents on the quinoline ring and the N-methyl group of the carboxamide.
Similar content being viewed by others
References
Srikrishnan, T. Anti-Cancer Drug Design 1990, 5, 213–220.
Srikrishnan, T.; Dasari, K.B.; Albini, B. Acta Crystallogr., Sect. A 1993, 49, 130.
Rooth, Walter.; Srikrishnan, T. J. Chem. Crystallogr. 1999, 29, 1187–1192.
Dasari, K. B.; Srikrishnan, T. J. Chem. Crystallogr. 2000, 30, 269–273.
Srikrishnan, T.; Dasari, K.B.; Zaleski, M.; Albini, B. In Proceedings of the XVI International Cancer Congress; Monduzzi Editore, Ed.; 1994, pp. 2817–2821.
Stalhandske, T.; Eriksoo, E.; Sanbderg, B.M. Int. J. Immunopharmacol. 1982, 4, 336–339.
Stalhandske, T.; Kalland, T. Immunopharmacology 1986, 11, 87–92.
Tarkowski, A.; Gunnarsson, K.; Nillsson, L.A. Arthritis Rheum. 1986, 29, 1405–1409.
Tarkowski, A.; Gunnarsson, K.; Stalhandske, T. Immunology 1986, 59, 589–594.
Kalland, T.; Alm, G.; Stalhandske, T. J. Immunol. 1985, 134, 3956–3961.
Kalland, T. J. Immunol. 1990, 144, 4472–4476.
Larsson, E.-L.; Joki, A.; Stalhandske, T. Int. J. Immunopharmacol. 1987, 9, 425–431.
Kalland, T. Cancer Res. 1986, 46, 3018–3022
Enraf-Nonius Structure Determination Package; Enraf-Nonius: Delft, The Netherlands, 1979.
Germain, G.; Main, P.; Woofson. M. M. Acta Crystallogr. Sect.A 1971, 27, 368–376.
Johnson, C.K. Report ORNL-3794; Oak Ridge National Laboratory: Tennessee, 1965.
Thomas, A.W. Immunol. Today 1989, 10, 6–9.
Tanaka, H. J. Am. Chem. Soc. 1987, 109, 5031–5033.
Starzl, T. Lancet 1989, 11, 1000–1004.
Tanak, H.; Kuroda, A.; Marusawa, H.; Hatanaka, F.; Kino, T.; Goto, T.; Hashimoto, M. J. Am. Chem. Soc. 1987, 109, 5031–5033.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dasari, K.B., Srikrishnan, T. Crystal structure and conformation of Linomide [N-methyl-N-phenyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide]: A novel immunomodulator. Journal of Chemical Crystallography 32, 499–504 (2002). https://doi.org/10.1023/A:1021153011803
Issue Date:
DOI: https://doi.org/10.1023/A:1021153011803